WO2013021784A1 - Inducteur de tolérance immunitaire - Google Patents

Inducteur de tolérance immunitaire Download PDF

Info

Publication number
WO2013021784A1
WO2013021784A1 PCT/JP2012/067950 JP2012067950W WO2013021784A1 WO 2013021784 A1 WO2013021784 A1 WO 2013021784A1 JP 2012067950 W JP2012067950 W JP 2012067950W WO 2013021784 A1 WO2013021784 A1 WO 2013021784A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
sirna
immune tolerance
spg
transplantation
Prior art date
Application number
PCT/JP2012/067950
Other languages
English (en)
Japanese (ja)
Inventor
康 梨井
櫻井　和朗
小林　正和
弘法 安藤
貞春 樋口
史郎 高原
Original Assignee
ナパジェン ファーマ，インコーポレテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2011/068265 external-priority patent/WO2012020795A1/fr
Priority claimed from PCT/JP2012/053583 external-priority patent/WO2012117855A1/fr
Application filed by ナパジェン ファーマ，インコーポレテッド filed Critical ナパジェン ファーマ，インコーポレテッド
Priority to EP12822876.4A priority Critical patent/EP2742944B1/fr
Priority to ES12822876.4T priority patent/ES2684969T3/es
Priority to US14/237,763 priority patent/US9801929B2/en
Priority to JP2013527942A priority patent/JP6210879B2/ja
Publication of WO2013021784A1 publication Critical patent/WO2013021784A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • the present invention relates to an immune tolerance inducer using a nucleic acid polysaccharide complex of siRNA and schizophyllan against a costimulatory factor.
  • the present invention also provides a method for inducing immune tolerance by controlling the function of a Dectin-1 expressing cell such as a dendritic cell by suppressing gene expression of a costimulatory factor using the nucleic acid polysaccharide complex, and
  • the present invention relates to a medicine used in the method.
  • the present invention relates to a drug that suppresses rejection in organ transplantation using a nucleic acid polysaccharide complex of siRNA and schizophyllan against costimulatory factors and induces immune tolerance.
  • RNA interference discovered in 1998, the magnitude and persistence of its effects are significantly superior to conventional antisense methods, and it is a revolutionary gene expression inhibition method that can be used in medicine. It has been expected.
  • double-stranded RNA that exhibits RNAi activity ie, siRNA
  • siRNA double-stranded RNA that exhibits RNAi activity
  • siRNA is often taken into the target cell after administration, or is often degraded in the cell, forming the RISC complex that is the active body in the cell. It was difficult. Therefore, although it is an excellent method for inhibiting gene expression, a sufficient effect cannot be obtained, so that there is no drug using siRNA yet.
  • transplantation treatment for transplanting donor cells, tissues, or organs has been established for patients with organ failure, hematological malignancy, etc., and transplantation treatment has become an indispensable treatment method in clinical practice.
  • improvements in techniques for suppressing recipient-specific immunity in recipients are desired in transplantation therapy.
  • There is no technology that can be derived and put into practical use see Non-Patent Documents 2 and 3).
  • the main object of the present invention is to provide a medicine and a method for effectively inducing donor-specific immune tolerance to a recipient in transplantation therapy.
  • a complex of siRNA against a costimulatory factor and schizophyllan is a dectin-1-expressing cell that specifically recognizes schizophyllan. It was discovered that the function of Dectin-1-expressing cells was delivered to regulate not only the immunosuppressive effect but also induce immune tolerance effectively. In fact, it was found that a heart transplantation model using a complex of siRNA against CD40 and schizophyllan exhibits a very excellent immune tolerance effect. The present invention has been completed as a result of further research based on these findings.
  • the present invention provides the following immune tolerance inducers, methods for inducing immune tolerance, and the like.
  • Item 1 An immune tolerance inducer used to induce donor specific immune tolerance to a recipient in transplantation treatment of donor cells, tissues or organs, comprising: An immunological tolerance inducer comprising a nucleic acid polysaccharide complex of siRNA and schizophyllan for a costimulatory factor.
  • Item 2. Item 2. The immunological tolerance inducer according to Item 1, wherein polydeoxyadenine is added to at least one end of the sense strand and the antisense strand in the siRNA.
  • Item 3. Item 3.
  • the immunological tolerance inducer according to Item 2 wherein at least a part of the phosphodiester bond in the polydeoxyadenine is phosphorothioated.
  • Item 4. Item 4. The immune tolerance inducer according to any one of Items 1 to 3, wherein the donor cell, tissue or organ is a bone marrow-derived cell.
  • Item 5. Item 5. The immune tolerance inducer according to any one of Items 1 to 4, wherein the costimulatory factor is a costimulatory factor expressed in a Dectin-1-expressing cell.
  • Item 6. Item 6. The immune tolerance inducer according to any one of Items 1 to 5, wherein the costimulatory factor is at least one selected from the group consisting of CD40, B7.1, and B7.2.
  • Item 7. Item 6.
  • the immune tolerance inducer according to any one of Items 1 to 5, wherein the costimulatory factor is CD40.
  • Item 8. The immune tolerance inducer according to any one of Items 1 to 7, wherein the transplantation treatment is kidney transplantation, heart transplantation, lung transplantation, bone marrow transplantation, skin transplantation, or corneal transplantation.
  • Item 9. A method for inducing immune tolerance in transplantation treatment, which comprises the step of administering a nucleic acid polysaccharide complex of siRNA to costimulatory factor and schizophyllan to an animal that requires immune tolerance to donor cells, organs or tissues.
  • Item 10. Nucleic acids of siRNA and schizophyllan for costimulators for the manufacture of an immune tolerance inducer used to induce donor specific immune tolerance to recipients in donor cell, tissue or organ transplantation therapy Use of polysaccharide conjugates.
  • the immune tolerance inducer of the present invention can effectively induce donor-specific immune tolerance in a recipient into which a donor cell, tissue or organ is transplanted. More specifically, according to the present invention, siRNA for co-stimulatory factor can be introduced into Dectin-1 expressing cells that have undergone or have undergone transplantation treatment to induce RNAi activity, By regulating the function of Dectin-1 expressing cells, immune tolerance can be induced in the recipient.
  • Example 4 It is a figure which shows the result of Example 4, ie, the RNA interference effect, even if siRNA linked S-poly (dA) is not cut
  • Example 10 shows that the result of (9-B) of Example 9, namely, dA40 (s) -siCD40 (21nt) / SPG complex significantly suppressed lymphocyte activation in ex ⁇ ⁇ ⁇ ⁇ vivo MLR.
  • the result of Example 10 ie, an image obtained by observing HEK293T cells and dHEK cells treated with Alexa647-labeled dA40 (s) -siLuc (21nt) / SPG complex is shown. The result of Example 10 is shown.
  • Example 13 shows that the result of (11-B) of Example 11, ie, activation of a lymphocyte was significantly suppressed by administration of dA40 (s) -siCD40 (21nt) / SPG complex.
  • Example 13 that is, in the ectopic heart transplantation model mouse administered with the dA40 (s) -siCD40 (21nt) / SPG complex, the pulsation of the transplanted heart was normal for a long time, and survival after transplantation It is a figure which shows that a rate is also high.
  • Example 14 the result of evaluating the immune tolerance effect of the dA40 (s) -siCD40 (21nt) / SPG complex in adoptive transfer (adoptive transfer) using an ectopic heart transplantation model mouse is shown.
  • Example 15 the result of having evaluated the immune tolerance effect of dA40 (s) -siCD40 (21nt) / SPG complex by MLR is shown.
  • the present invention relates to an immune tolerance inducer used for inducing donor-specific immune tolerance to a recipient in the transplantation treatment of donor cells, tissues or organs, comprising an siRNA against a costimulatory factor and schizophyllan. It contains a nucleic acid polysaccharide complex.
  • an immune tolerance inducer used for inducing donor-specific immune tolerance to a recipient in the transplantation treatment of donor cells, tissues or organs, comprising an siRNA against a costimulatory factor and schizophyllan. It contains a nucleic acid polysaccharide complex.
  • the target of siRNA used in the present invention may be a costimulatory factor (also referred to as a costimulatory molecule), and preferably a costimulatory factor expressed in Dectin-1 expressing cells.
  • Dectin-1 is a receptor (Pattern Recognition Receptor) having a C-type leptin-type sugar chain recognition domain present on the cell membrane. Dectin-1 has a region that specifically recognizes ⁇ -1,3-glucan outside the cell, and has a motif that conveys an activation signal called ITAM (immunoreceptor tyrosinase-based activation motif-1) inside the cell .
  • ITAM immunomunoreceptor tyrosinase-based activation motif-1
  • Dectin-1 When Dectin-1 recognizes ⁇ -1,3-glucan, it promotes the production of NF- ⁇ B and inflammatory cytokines and triggers a host defense reaction.
  • the Dectin-1-expressing cells include macrophages, dendritic cells, neutrophils and the like.
  • Schizophyllan has a ⁇ -1,3-glucan skeleton and is delivered into the Dectin-1 expression details through signals induced by binding to Dectin-1 present in the cell membrane of Dectin-1 expressing cells It is known.
  • the nucleic acid polysaccharide complex used in the present invention is delivered into a Dectin-1-expressing cell upon recognition of its constituent component schizophyllan by Dectin-1.
  • siRNA contained in the nucleic acid polysaccharide complex used in the present invention can efficiently induce immune tolerance in the recipient by selecting a costimulatory factor expressed in Dectin-1-expressing cells. .
  • costimulatory factors expressed in Dectin-1 expressing cells include CD40, B7.1 (CD80) and B7.2 (CD86).
  • Examples of the target gene of siRNA used in the present invention include at least one of these genes, and particularly preferred is the CD40 gene.
  • the base sequence of “siRNA against costimulatory factor” used in the present invention can be appropriately determined according to the type of target costimulatory factor.
  • the siRNA for the costimulatory factor may contain a sequence that is 100% identical to a part of the base sequence of the target costimulatory factor, and as long as the desired RNA interference effect is obtained, the 100% identity
  • a sequence in which one or several bases are substituted / added to the sequence to be added may be included.
  • both the sense strand RNA and the antisense strand are composed of 21 ribonucleotides, and the 5 ′ end of the sense strand RNA And those in which a dangling end composed of two ribonucleotides is formed at the 5 ′ end of the antisense strand RNA. That is, in the case of such double-stranded RNA, the 1-19th ribonucleotide sequence from the 3 ′ end of the antisense strand RNA is the 3-21st ribonucleotide sequence from the 5 ′ end of the sense strand RNA. A sequence complementary to a nucleotide.
  • Such 21mer siRNA is also referred to herein as 21mer siRNA. 21mer siRNA has the property of not being cleaved by Dicer.
  • the siRNA for the costimulatory factor may be any as long as it can be complexed with schizophyllan, for example, conjugated with schizophyllan at at least one end of the sense strand or antisense strand that constitutes the siRNA for the costimulatory factor gene. It is only necessary to add a molecule that can be used (hereinafter also referred to as “SPG-binding molecule”).
  • the SPG-binding molecule may be directly bonded to the terminal ribonucleotide of the siRNA sense strand RNA and / or the antisense strand RNA to the costimulatory factor, or may be bonded via a linker (spacer). .
  • the number of SPG binding molecules added to the siRNA is not particularly limited.
  • the number of SPG binding molecules to siRNA is 1, and the SPG binding molecule is bound to the 5 ′ end of the sense strand of the siRNA. Things.
  • the SPG binding molecule is bound only to the 5 ′ end of the sense strand of the siRNA, the RNA interference effect based on the siRNA can be made remarkable.
  • an SPG-binding molecule may be bound to either the sense strand / antisense strand or the 5 ′ end / 3 ′ end. When bound to the 5 ′ end, an excellent RNA interference effect can be exhibited.
  • the type of the SPG-binding molecule is not particularly limited as long as it can be complexed with schizophyllan, but is preferably a nucleic acid, more preferably polydeoxyadenine (hereinafter sometimes referred to as “poly (dA)”). Can be mentioned.
  • poly (dA) polydeoxyadenine
  • a single triple strand of poly (dA) and a double strand of schizophyllan can form a stable triple helical structure.
  • the number of deoxyadenines constituting the poly (dA) is not particularly limited as long as it can form a complex with schizophyllan described later. Although not intended, examples include 10 to 100, preferably 20 to 100, more preferably 20 to 80, and still more preferably 30 to 50.
  • poly (dA) when poly (dA) is used as the SPG-binding molecule, it is preferable that at least a part of the phosphodiester bond of poly (dA) is phosphorothioated (S).
  • the S conversion rate of poly (dA) is usually 50% or more, preferably 80% or more, and more preferably 100%.
  • the S conversion rate of poly (dA) indicates the ratio (%) of phosphodiester bonds that have been converted to S with respect to the total number of phosphodiester bonds in poly (dA).
  • the S-phosphodiester bond is a bond structure in which one oxygen atom of the phosphate residue of the phosphodiester bond portion is substituted with a sulfur atom.
  • Poly (dA) can be converted to S according to a conventionally known method.
  • the distribution of S conversion in poly (dA) is not particularly limited, and desired S conversion may be performed at an arbitrary position.
  • S-poly (dA) forms a good complex with schizophyllan, and the nucleic acid polysaccharide complex thus obtained has a high resistance to degrading enzymes.
  • S-modified poly (dA) when S-modified poly (dA) is added to the sense strand, the nucleic acid polysaccharide complex of the siRNA and schizophyllan can be obtained by incorporating the antisense strand into the RISC complex. The RNA interference effect can be effectively exhibited.
  • Schizophyllan Schizophyllan (hereinafter sometimes referred to as “SPG”) is a polysaccharide with a ⁇ -1,3-glucan skeleton and binds to the receptor (Dctin-1) present on the surface of Dectin-1-expressing cells Is delivered in detail through a signal induced by
  • SPG can be produced according to a standard method described in the literature (A.C.S.38 (1), 253 (1997); Carbohydrate Research, 89, 121-135 (1981)).
  • the SPG thus obtained can obtain schizophyllan having a desired molecular weight by sonication.
  • the SPG used in the present invention may be one in which various functional molecules are bound.
  • the binding ratio of the functional molecule is, for example, 1 to 200, preferably 1 to 100, particularly preferably 1 to 100 functional molecules per 100 side chains of SPG. 50 are illustrated.
  • the binding ratio of such a functional molecule can be adjusted by controlling the amount of an oxidizing agent such as sodium periodate added to the branched glucose residue in the above production method.
  • the binding site of the functional molecule to SPG and the site that binds the linker that links the functional molecule are not particularly limited, but are separated from the main chain of ⁇ -1,3-glucan of SPG. It is preferable that the 1,2-diol site of glucose having a branched 1,6-glucopyranoside bond is substituted and bonded.
  • the molecular weight of the SPG used in the present invention is not particularly limited, and may be appropriately set according to the chain length of the SPG-binding molecule such as poly (dA) described above. Specifically, the molecular weight of SPG is usually 25,000 to 500,000, preferably 25,000 to 250,000.
  • Nucleic acid polysaccharide complex of siRNA and costofactor for costimulatory factor uses a nucleic acid polysaccharide complex of siRNA and SPG for costimulatory factor.
  • the nucleic acid polysaccharide complex can be obtained by complexing an SPG-binding molecule added to siRNA against a costimulatory factor and schizophyllan.
  • poly (dA) which may be S-modified, is added to at least one end of the sense strand or antisense strand constituting the siRNA for the costimulatory factor gene.
  • poly (dA) which may be S-modified
  • a composite molecule in which a triple helix is formed by one strand of (dA) and two strands of schizophyllan can be mentioned.
  • the nucleic acid polysaccharide complex can be prepared according to a known method. Specifically, a method of producing in the following steps (1) to (3) is exemplified: (1) An siRNA in which the SPG-binding molecule is bound directly or via a linker is prepared according to a known method. , (2) Separately, SPG is prepared, or SPG (modified SPG) in which functional molecules are bound directly or via a linker (modified SPG) is prepared. (3) Next, SPG binding property bound to siRNA A complex is formed using the molecule and the SPG or the modified SPG.
  • the mixing ratio of the siRNA and the SPG or the modified SPG is appropriately selected according to the chain length of the SPG binding molecule or the chain length of the SPG or the modified SPG. can do.
  • poly (dA) is used as the SPG-binding molecule
  • one molecule of SPG main chain corresponds to one molecule of poly (dA) adenine
  • one poly (dA) and two SPGs Take a triple helix structure. That is, when siRNA to which poly (dA) is added is used, the nucleic acid polysaccharide complex incorporates poly (dA) into one or more of the double helix structure formed by two SPGs. A triple helix structure is formed.
  • an siRNA with 40mer poly (dA) added and an SPG with a molecular weight of 150,000 can have a triple helix structure containing 17 molecules of siRNA with 40mer poly (dA) added to two SPG2 molecules with a molecular weight of 150,000. it can.
  • the preferred molar ratio of siRNA added with poly (dA) and SPG is 20: 1 to 1: 5, preferably 10: 1 to 1: 1, and the single strand of the polynucleotide-bound double-stranded RNA. It is preferable to complex the polydeoxyadenine region with the SPG or the modified SPG. By exposing the siRNA and the SPG or the modified SPG to complex formation conditions at such a molar ratio, the two can be efficiently interacted and used in the present invention. The production efficiency of the nucleic acid polysaccharide complex can be improved.
  • a nucleic acid polysaccharide complex formed with a triple-stranded helical structure using siRNA to which poly (dA) is added and schizophyllan is specifically prepared according to the following method.
  • SPG has a triple helix structure in nature or in water. This SPG is dissolved in a polar solvent such as DMSO (dimethyl sulfoxide) or an alkaline aqueous solution such as an aqueous solution of sodium hydroxide and denatured to a single strand. Then, siRNA added with poly (dA) is added, and the solvent is washed with water.
  • DMSO dimethyl sulfoxide
  • alkaline aqueous solution such as an aqueous solution of sodium hydroxide
  • association structure consisting of a single strand part of poly (dA) linked to siRNA and two SPGs ) Is formed.
  • association structure consisting of a single strand part of poly (dA) linked to siRNA and two SPGs .
  • the immunological tolerance inducing agents of the present invention are used to induce donor specific immune tolerance in a recipient who has undergone or undergoes transplantation of donor cells, tissues or organs.
  • donor specific immune tolerance in a recipient who has undergone or undergoes transplantation of donor cells, tissues or organs.
  • nucleic acid polysaccharide complex By using the above-mentioned nucleic acid polysaccharide complex, it is possible to suppress the expression of the costimulatory factor gene in a specific manner in a Dectin-1-expressing cell in a recipient who has undergone or has undergone transplantation treatment, and effective donor-specific immune tolerance. Can be guided to.
  • the immunological tolerance inducer of the present invention can be applied to animals such as humans, monkeys, mice, rats, dogs, rabbits, cats, cows, chickens, etc., preferably humans.
  • the immunological tolerance inducer of the present invention can be prepared by containing the nucleic acid polysaccharide complex in an effective amount for inducing immune tolerance and further combining pharmaceutically acceptable carriers as appropriate.
  • pharmaceutically acceptable carriers include aqueous carriers such as purified water, sugar-containing aqueous solutions, buffers, physiological saline, and nuclease-free water; excipients and the like.
  • the administration route of the immunological tolerance inducer of the present invention includes oral, parenteral (including intravenous, intraperitoneal, intramuscular, subcutaneous, rectal, and intravaginal administration), inhalation, systemic administration, and local administration (skin and buccal surfaces). From conventional methods based on the patient's symptoms, disease state, type of disease, etc., including external application to the cavity; including instillation into sites that do not substantially enter the bloodstream such as the eyes, ears, and nose) It can be selected appropriately.
  • the transplantation treatment using the immunological tolerance inducer of the present invention includes a method of administering the immunological tolerance inducer of the present invention to a donor that provides transplanted cells, tissues or organs, and transplanted cells, tissues or organs with the present immunological tolerance inducers. It is performed by a method of treatment, a method of administering to a recipient who receives transplantation of cells, tissues or organs, or a method of combining these two or three.
  • the transplanted cells, organs or tissues are not particularly limited, and examples thereof include bone marrow-derived cells, kidney, heart, lung, bone marrow, skin, cornea and the like. Can be mentioned.
  • the immunological tolerance inducer of the present invention can induce not only resistance or rejection of transplanted cells, organs or tissues, but also induction of immunological tolerance, administration of the immunosuppressive agent is stopped at an early stage after transplantation. However, it is possible to suppress the occurrence of immune rejection. Also, prior to living liver transplantation, living kidney transplantation, etc., the immune tolerance inducer of the present invention is administered when inducing immune tolerance to the recipient by transplanting donor bone marrow-derived cells. Therefore, it is possible to promote the survival of transplanted liver and kidney and avoid rejection.
  • the immunotolerant of the present invention is a skin symptom of autoimmune diseases, inflammatory diseases, proliferative and hyperproliferative diseases, and immunologically mediated diseases (eg, rheumatoid arthritis, lupus erythematosus, systemic lupus erythematosus, Hashimoto thyroiditis, multiple sclerosis, myasthenia gravis, type 1 diabetes, uveitis, nephrotic syndrome, psoriasis, atopic dermatitis, contact dermatitis, eczema dermatitis, seborrheic dermatitis, flat lichen Treatment or prevention of pemphigus, bullous pemphigoid, epidermolysis bullosa, hives, angioedema, vasculitis, erythema, cutaneous eosinophilia, alopecia areata, etc .; reversible airway disease (reversible obstructive
  • the dosage of the immunological tolerance inducer of the present invention in transplantation treatment may be any effective and non-toxic amount for inducing immune tolerance, and the dosage is determined by a person skilled in the art through routine experiments.
  • the effective dose is usually in the range of about 0.001 to 10 mg per kg body weight per day. Selected from.
  • the present invention also provides a nucleic acid polysaccharide complex for producing an immune tolerance inducer used for inducing donor-specific immune tolerance when a donor cell, tissue or organ is transplanted into a recipient. Also provides use. Furthermore, the present invention provides a method for inducing immune tolerance comprising the step of administering the above-mentioned nucleic acid polysaccharide complex to an animal in need of immune tolerance to donor cells, organs or tissues. In particular, the present invention also provides the use of the above-mentioned nucleic acid polysaccharide complex for the manufacture of a preparation for suppressing rejection in transplantation therapy and inducing immune tolerance.
  • the present invention provides a method for suppressing rejection in transplantation treatment or induction of immune tolerance, comprising the step of administering the nucleic acid polysaccharide complex to an animal in need of treatment or prevention of rejection of a transplanted organ or tissue.
  • a method for suppressing rejection in transplantation treatment or induction of immune tolerance comprising the step of administering the nucleic acid polysaccharide complex to an animal in need of treatment or prevention of rejection of a transplanted organ or tissue.
  • siRNA for luciferase is sometimes referred to as “siLuc”
  • siRNA for CD40 is sometimes referred to as “siCD40”.
  • Example 1 Formation of nucleic acid polysaccharide complex of SPG and siRNA
  • the nucleic acid polysaccharide complex used in the following examples was formed as follows. After preparing SPG having a molecular weight of about 150,000 in a 0.25N aqueous sodium hydroxide solution to a final concentration of 15 mg / ml, the mixture was vibrated with stirring for 1 hour and allowed to stand at 4 ° C. for 1 day for denaturation. A solution of siRNA added with S-modified poly (dA) dissolved in 330 mM primary sodium phosphate was added to this denatured SPG solution, neutralized, and allowed to stand at 4 ° C. for 24 hours or more.
  • dA S-modified poly
  • siRNA to which S-modified poly (dA) has been added is one in which 40 deoxyadenines phosphorothioated at the 5 ′ end of the sense strand of siRNA are linked by a phosphate ester bond.
  • S-poly (dA) may be abbreviated as dA40 (s).
  • the S conversion rate of S-polydeoxyadenine used in the following examples is 100%.
  • Example 2 Stability of nucleic acid polysaccharide complex of siRNA added with S-poly (dA) and SPG in cell culture medium
  • PBS phosphate buffer solution
  • cell culture medium (10% FBS + RPMI (FBS; Biological Industry Cat # 04-001-1A, RPMI; Wako Pure Chemical Industries, Ltd. Cat # 189-02025)).
  • FBS + RPMI FBS
  • RPMI Biological Industry Cat # 04-001-1A, RPMI; Wako Pure Chemical Industries, Ltd. Cat # 189-02025
  • TBE Tris-boric acid-EDTA
  • dA40 (s)-siLuc (21nt) represents a 21mer siRNA against luciferase (SEQ ID NO: 1) added with 40mer polydeoxyadenine phosphothioated at the 5 'end of the sense strand.
  • dA40 (s) -siLuc (27nt) represents a 27mer siRNA (SEQ ID NO: 3) for luciferase with 40mer polydeoxyadenine phosphothioated at the 5 'end of the sense strand.
  • siRNA added with 40mer poly (dA) phosphothioated cells in which the degradation enzyme is present and siRNA and SPG do not form a complex (lanes 2 and 5) are control lanes.
  • the bands at positions 1 and 4 are thinly decomposed, but those in which siRNA and SPG form a complex (lanes 3, 6, and 7) are dark bands, indicating that they are stable as nucleic acid polysaccharide complexes. It was done.
  • siRNA added with non-phosphorothioated poly (dA) the phosphothioated one was more stable in the cell culture medium in which the degrading enzyme was present.
  • Example 3 Dicer sensitivity of nucleic acid polysaccharide complex (3-1) Dicer sensitivity of non-S-modified dA tail nucleic acid polysaccharide complex
  • a Recombinant human dicer enzyme kit Genlantis, Cat # T510002 was used.
  • premixes having the following compositions (A to E) were prepared.
  • siCD40 (21 nt) represents a 21mer siRNA against CD40 (SEQ ID NOs: 5 and 6).
  • dA40-siCD40 (21 nt) represents a 21mer siRNA against CD40 (SEQ ID NOs: 5 and 6) with 40mer polydeoxyadenine added to the 5 'end of the sense strand (SEQ ID NO: 5).
  • siLuc21 represents a 21mer siRNA against the luciferase shown in SEQ ID NOs: 1 and 2.
  • dA40-siLuc 21 nt represents a 21-mer siRNA against luciferase (SEQ ID NOs: 1 and 2) with 40-mer polydeoxyadenine added to the 5 'end of the sense strand (SEQ ID NO: 1).
  • siLuc (21nt) represents a 21mer siRNA (SEQ ID NOs: 1 and 2) for luciferase.
  • siLuc (27nt) represents a 27mer siRNA (SEQ ID NO: 3 and 4) for luciferase.
  • dA40 (s) -siCD40 (21nt) represents 21mer siRNA against CD40 (SEQ ID NOs: 5 and 6) with 40mer polydeoxyadenine phosphothioated at the 5 'end of the sense strand (SEQ ID NO: 5). .
  • dA40 (s) -siCD40 (27nt) represents a 27mer siRNA against CD40 (SEQ ID NO: 7 and 8) with a 40mer polydeoxyadenine phosphothioated at the 5 ′ end of the sense strand (SEQ ID NO: 7). .
  • the band of lane 6 has the same density as the control lane 4 and lane 5, and even when S-poly dA was added, 21nt siRNA was not cleaved by Dicer. However, the lane 12 band was thinner than the control lane 10 and lane 11 bands, indicating that the 27 nt siRNA was cleaved by Dicer.
  • Example 4 RNA interference effect of siRNA ligated with poly (dA) Dual Luciferase expression vector psiCHECK TM -2 (Promega Cat # C8021) and Lipofectamine TM LTX (Life Technologies Japan Cat # 15338-500) Introduced into HEK293 cells. At this time, the number of cells per well was adjusted to 50,000. To this, dA40-siLuc (21 nt) or dA40-siLuc (27 nt) is introduced into the cells using TransIT TM -TKO (Takara Bio, Cat # V2154) and incubated at 37 ° C. for 20 hours in a CO 2 incubator. did.
  • RNA interference effect was expressed by comparing the expression of two luciferases in the control, assuming that the RNA interference effect at that time was 0%, and the percentage of expression suppression in each sample in%.
  • Example 5 RNA interference effect of siRNA / SPG complex to which S-modified poly (dA) is linked RNA interference effect using a complex of phosphorylated and polythiophene poly (dA) chimera siRNA and SPG was analyzed by Dual Luciferase assay ( Evaluation was carried out using a Dual-Glo Luciferase assay system, Cat # E2920) manufactured by Promega.
  • the cells used were RAW264.7 cells (dRAW cells) that strongly express Dectin-1 (obtained from Associate Professor Yasuyuki Adachi, Department of Immunology, Tokyo Pharmaceutical University).
  • the samples used are as shown in Table 4 below.
  • Sample 4 is obtained by introducing dA40 (s) -siLuc (21 nt) using TransIT TM -TKO (Takara Bio Inc., Cat # V2154).
  • Table 4 shows that an RNA interference effect can be obtained with a poly (dA) (s) -siRNA / SPG complex.
  • Example 6 Dose dependency of RNA interference effect by poly (dA) (s) -siRNA complex
  • dRAW cells showing proliferative properties in 10% serum culture were used. Samples used in this example are shown in Table 5 below.
  • dRAW cells were collected, seeded in a 48-well plate at 20000 cells / well / 200 ⁇ l, and incubated for 20 hours in a 37 ° C. CO 2 incubator.
  • the psiCHECK TM -2 / LTX complex was mixed at 20 ⁇ l / well and the medium at 180 ⁇ l / well and added to a 48-well plate.
  • Dual Luc assay Promega, Dual-Glo Luciferase assay system, Cat #: E2920 was performed. The results are shown in Table 5 below.
  • Table 5 shows that the RNA interference effect can be obtained in a dose-dependent manner with the poly (dA) (s) -siRNA complex.
  • Example 7 Cell introduction of poly (dA) (s) -siRNA complex (7-A) Introduction to dRAW cells dRAW cells were seeded at 1000000 cells / dish (5 ml), and 37 Incubation was performed for 20 hours in a CO 2 incubator at 0 ° C. Thereafter, Alexa 647-labeled naked dA40 (s) siLuc (21nt) and Alexa 647-labeled dA40 (s) siLuc (21nt) / SPG complex were added to the medium at a concentration of 100 nM, respectively, and contacted with dRAW cells. Cells were harvested 1, 2, 4 and 8 hours after the addition of each siRNA. The collected cells were fixed with 10% equilibrated formaldehyde (100 ⁇ l / dish), and the number of cells labeled with Alexia647 was measured by flow cytometry (FACS).
  • FACS flow cytometry
  • dA40 (s) siLuc (21nt) / SPG complex has more than twice the number of cells labeled with Alexia647, and dA40 (s) siLuc It is thought that the intracellular uptake of (21nt) / SPG complex is more than doubled.
  • CD11c (+) Spleen cells were obtained from mice (C57BL / 6, male, 7 weeks old; 4 mice) according to a conventional method. A part of the obtained spleen cells was stored on ice for use as a control. The remaining spleen cells were separated into a CD11c ( ⁇ ) cell group and a CD11c (+) cell group using a MACS MS column. Separation of cells by the column was performed twice. A CD11c (+) cell group was prepared to 7 ⁇ 10 5 cells, and cultured for 48 hours (37 ° C .; 5% CO 2 ) in a 6-well plate (volume 2 ml) under the conditions shown in Table 6 below.
  • Dectin-1-FITC represents an anti-Dectin-1 antibody modified with FITC
  • CD11c-FITC represents an anti-CD11c antibody modified with FITC
  • PE Isotype control represents an isotype control antibody modified with PE. .
  • sample 5 has a lower proportion of Dectin-1 positive cells than sample 4
  • sample 7 has a lower proportion of Dectin-1 positive cells than samples 4 and 6
  • siRNA / SPG complex expresses Dectin-1 When incorporated into cells, it was confirmed that the expression level of Dectin-1 in the cells decreased.
  • Spleen cells were obtained from mice (C57BL / 6, male, 7 weeks old; 4 mice) according to a conventional method. A part of the obtained spleen cells was stored on ice for use as a control. The remaining spleen cells were separated into a CD11c ( ⁇ ) cell group and a CD11c (+) cell group using a MACS MS column. Separation of cells by the column was performed twice. A CD11c (+) cell group was prepared to 2 ⁇ 10 4 cells, and cultured for 24 hours (37 ° C .; 5% CO 2 ) in a chamber cover glass (4 wells, volume 1 ml / well).
  • the antibody solution was removed by aspiration, and washing was performed 3 times.
  • Alexa-488-anti-mouse IgG antibody (Life Technologies Japan) was diluted 750 times with Triton X-100, 1.5% NGS, BSA / PBS, and incubated at room temperature for 1 hour.
  • the antibody solution was removed by aspiration, and washing was performed 3 times.
  • the chamber was removed and mounted with a mounting medium containing an anti-fading agent. This sample was photographed and analyzed with a laser confocal microscope.
  • siRNA taken into the cell by the dA40 (s) siLuc / SPG complex and TRBP2, the core protein of RLC, are localized at the same position and the images match at the same depth of focus.
  • siRNA taken into the cell and TRBP2 exist at a distance that allows interaction that is, siRNA was taken into RLC.
  • siLuc alone labeled with Alexa647 the incorporated siLuc could not be observed.
  • cDNA was synthesized using PrimerScript RT reagent Kit (Takara Bio Inc., cat No RR037A). The synthesized cDNA was subjected to real time qPCR using SYBR Prime Ex Taq II (Takara Bio Inc., cat No RR081A) to measure the expression level of CD40 mRNA. At the same time, the expression level of beta-actin mRNA was measured and used to correct the measured value of CD40 mRNA. The corrected value was defined as the CD40 mRNA expression level under each condition.
  • the primer sequences used for qPCR are as shown in Table 8.
  • FACS CD11 (+) cells in mouse spleen cells were isolated, and the ratio of CD40-positive cells in CD11 (+) cells was analyzed by FACS. Furthermore, the cells were added to the same environment as the cell culture, that is, 10% FBS + RPMI medium, heated to 37 ° C. by CO 2 incubation, and cultured for 4 to 48 hours as specified. At this time, CD11 (+) cells were treated with SPG, naked dA40 (s) siCD40 (27nt) and dA40 (s) siCD40 (27nt) / SPG complex, and the subsequent CD40 expression was analyzed by FACS. The method for treating spleen cells is as described in (7-B) above. The antibodies used in FACS are shown in parentheses in Table 9 below. In the table, PE Isotype control represents an isotype control antibody modified with PE, and CD40-PE represents an anti-CD40 antibody modified with PE.
  • siRNA is stabilized in serum and blood by forming a complex of siRNA and SPG, so that the efficiency of introduction into cells is improved compared to naked siRNA, and even into the cytoplasm.
  • siRNA it is considered that mRNA expression was suppressed and expression of target molecules on the cell membrane surface was suppressed.
  • Example 8 The costimulatory factor CD40, which is known as an early response factor of immune response, was set as a target molecule, and cells of Responder mouse were treated with siRNA against this molecule. The pharmacological effect was evaluated by performing MLR (Mixed Lymphocyte Reaction) between Stimulator cells and siRNA untreated or treated Responder cells, and measuring each cell proliferation rate with a BrdU chemiluminescence kit.
  • MLR Mated Lymphocyte Reaction
  • CD11c (-) Responder spleen cells When MLR is performed, if CD11c (-) Responder spleen cells are used, antigen-presenting cells (Antigen Presenting Cells; APC) are deficient, and normal lymphocyte reaction is suppressed and cell proliferation is suppressed.
  • CD11c (+) spleen cells treated with siCD40 / SPG complex were added, and the degree of recovery of cell proliferation was observed.
  • Comparison of the allogeneic MLR and the syngenic MLR with or without the addition of dA40 (s) -siCD40 (27nt) / SPG complex revealed that the addition of dA40 (s) -siCD40 (27nt) / SPG complex was significant. It was confirmed that induction of immunosuppression was achieved (the degree of recovery of cell proliferation decreased: FIGS. 2 and 3).
  • C57BL / 6 mice were used as Responder mice, and Balb / c was used as a Stimulator mouse.
  • Stimulator spleen cells were used by adding mitomycin C (MMC) at the time of collection to stop cell proliferation.
  • Pre-culture in vitro MLR is the addition of siCD40 / SPG complex to CD11c positive cells isolated from Responder mouse spleen cells, then returned to CD11 negative cells, and then mixed with mitomycin C (MMC) treated Stimulator spleen cells.
  • MMC mitomycin C
  • Spleen cells were collected from mice (Balb / c (9 males; 2 mice), C57BL / 6 (9 males; 2 mice)).
  • Hemolyzing agents ammonium chloride, potassium
  • lyse red blood cells hemolytic agent 5 ml, RPMI 5 ml
  • FBS DS Pharma Biomedical
  • MMC mitomycin C
  • CD11c positive cells Magnetic labeling
  • the CD11c positive cells recovered by the addition of the complex group were divided into 1.0 ⁇ 10 5 cells / condition. Naked siCD40 and siCD40 / SPG complexes were added to a final concentration of 100 nM, and incubation was performed at 37 ° C. for 4 hours. MLR used was 5 ⁇ 10 5 responder (splenocyte) and 5 ⁇ 10 5 stimulator (mixture of CD11c positive cells 2.5 ⁇ 10 4 and CD11c negative cells 4.75 ⁇ 10 5 ). The MLR conditions are shown in Table 10 below.
  • FIG. 2 shows the inhibition rate of the growth recovery due to the allo reaction.
  • Cell proliferation was not confirmed when MLR was applied to Balb / c whole spleen cells and CD11c (-) cells isolated from C57BL / 6.
  • MLR was performed on Balb / c whole spleen cells and CD11c ( ⁇ / +) cells isolated from C57BL / 6, the allogenic reaction was activated and the cell proliferation response was recovered.
  • CD11c (+) cells which were target cells, and mixed with CD11c ( ⁇ ) cells and subjected to MLR with Balb spleen cells, cell growth recovery was suppressed. That is, CD11c positive cells were shown to induce immunosuppression in precultured MLR.
  • FIG. 3 shows the MLR results.
  • FIG. 3 shows that CD11c positive cells induce immunosuppression in a pre-cultured MLR in a dose-dependent manner.
  • Example 9 (9-A) in vitro MLR
  • the cell preparation method is as follows.
  • Spleen cells were collected from mice (stimulator: Balb / c (male 7 weeks old; 2 mice), responder: C57BL / 6 (male 7 weeks old; 2 mice)).
  • Hemolyzing agents ammonium chloride, potassium
  • lyse red blood cells hemolytic agent 3 ml, 2 minutes.
  • 8 ml of RPMI was added and centrifuged at 300 ⁇ g for 10 minutes. The supernatant was removed with an aspirator, 10 ml of RPMI was added thereto, and the cells were suspended. After the centrifugation operation, the same operation was repeated.
  • the cells were suspended with 5 ml of 10% FBS / RPMI, and the number of cells was counted.
  • Stimulator-side spleen cells were treated with mitomycin C (MMC) (37 ° C., 30 minutes) (25 ⁇ g of MMC added to the final 10 7 cells).
  • MMC mitomycin C
  • the cells were suspended in 10 ml of RPMI and centrifuged at 300 ⁇ g for 10 minutes. The supernatant was removed with an aspirator, 10 ml of RPMI was added thereto, and the same operation was repeated 4 times after the centrifugation operation.
  • the cells were suspended in 3 ml of 10% FBS / RPMI, the number of cells was counted, and the cell concentration was adjusted to 5 ⁇ 10 6 cells / ml.
  • the complex (or siMOCK) was added to the spleen cells on the Responder side (5 ⁇ 10 6 cells for each condition) to a final concentration of 10 nM and cultured at 37 ° C. for 4 hours.
  • 10 ml of RPMI was added to the cell suspension and suspended, and centrifuged at 300 ⁇ g for 10 minutes.
  • the supernatant was removed with an aspirator, 10 ml of RPMI was added thereto, and the same operation was repeated twice after the centrifugation operation.
  • the cells were suspended in 1 ml of 10% FBS / RPMI, the number of cells was counted, and the cell concentration was adjusted to 5 ⁇ 10 6 cells / ml. 5 ⁇ 10 5 Stimulator cells and 5 Responder cells were mixed in 1 well (final volume 200 ml / well) and cultured for 72 hours in a 37 ° C., 5% CO 2 environment. After culture, cell proliferation was measured by an assay using chemiluminescence by BrdU incorporation (Cell Proliferation ELISA, BrdU) (Roche Applied Science).
  • MLR In vitro MLR was also performed in which siRNA was processed on Stimulator spleen cells. Stimulator cells were treated according to the above procedures except that siRNA treatment was performed after MMC treatment, and that Responder cells were stored in an ice-cold state until the start of MLR without treatment after counting the number of cells. Table 12 shows the MLR conditions.
  • Spleen cells were collected from mice (stimulator: Balb / c (male 8 weeks old; 3 mice), responder: C57BL / 6 (male 8 weeks old; 3 mice)). Responder mice were administered the siRNA / SPG complex intravenously 4 hours before harvesting the spleen cells.
  • Hemolyzing agents ammonium chloride, potassium
  • lyse red blood cells hemolytic agent 5 ml, RPMI 5 ml
  • 10% FBS DS Pharma Biomedical
  • stimulator-side spleen cells were treated with mitomycin C (MMC) (for the final 10 7 cells) 25 ⁇ g MMC added).
  • MMC mitomycin C
  • FIG. 4 the value obtained by subtracting the value of the syngenic response from the value of the control allogenic response (splenocyte activity) (the value obtained by subtracting the number of cells of sample 2 from the number of cells of sample 6) is plotted as 100%. It shows how much the response of lymphocyte proliferation by allogeneic reaction could be suppressed by administration of dA40 (s) -siCD40 (21nt) / SPG complex. From this result, it was revealed that dA40 (s) -siCD40 (21nt) / SPG complex significantly suppressed lymphocyte activation upon in vivo administration.
  • Example 10 Intracellular uptake specific to Dectin-1 expressing cells
  • Alexa647-labeled dA40 (s) -siLuc (21nt) / SPG complex was specifically taken up into Dectin-1 expressing cells.
  • the test method is as follows.
  • the fixed cells were observed with a laser confocal microscope (Carl Zeiss LSM710 NLO System), and further, the fluorescence intensity of Alexa647 exhibited by the cells was measured by flow cytometry. Furthermore, the amount of Dectin-1 expressed on the cell surface of the fixed cells using a FITC-labeled antibody was measured by flow cytometry.
  • HEK293T cells used in this test are human fetal kidney epithelial cells not expressing Dectin-1, and dHEK cells are cells that have been transformed to express Dectin-1 in HEK293T cells.
  • FIG. 5 shows an image obtained by observing cells treated with Alexa647-labeled dA40 (s) -siLuc (21nt) / SPG complex
  • FIG. 6A shows Alexa647-labeled dA40 (s) -siLuc (21nt).
  • FIG. 6B shows the result of measuring the fluorescence intensity of FITC for the cells treated with Alexa647-labeled dA40 (s) -siLuc (21nt).
  • Example 11 In this study, dA40 (s) -siCD40 (21nt) / SPG complex was administered to Responder mice by tail vein injection (iv), and spleen cells were collected after 4 hours, and MLR with Stimulator mouse spleen cells was performed. The behavior of siRNA in vivo was confirmed.
  • the cell preparation method is as follows.
  • Spleen cells were collected from mice (stimulator: Balb / c (male 8 weeks old; 3 mice), responder: C57BL / 6 (male 8 weeks old; 3 mice)). Responder mice were administered the siRNA / SPG complex intravenously 4 hours before harvesting the spleen cells.
  • Hemolyzing agents ammonium chloride, potassium
  • lyse red blood cells hemolytic agent 5 ml, RPMI 5 ml.
  • 10% FBS DS Pharma Biomedical
  • stimulator-side spleen cells were treated with mitomycin C (MMC) (for the final 10 7 cells) 25 ⁇ g MMC added). Table 14 shows the MLR conditions.
  • FIG. 7 the value (splenocyte activity) obtained by subtracting the numerical value of the syngenic reaction from the numerical value of the control allogenic response (the value obtained by subtracting the number of cells of sample 6 from the number of cells of sample 6) is plotted as 100%. It shows how much the response of lymphocyte proliferation by allogeneic reaction could be suppressed by administration of dA40 (s) -siCD40 (21nt) / SPG complex. From this result, it was revealed that dA40 (s) -siCD40 (21nt) / SPG complex significantly suppressed lymphocyte activation upon in vivo administration.
  • dA40 (s) -siCD40 (21nt) / SPG complex was administered to both Responder mice and Stimulator mice by tail vein injection (iv), and spleen cells were collected after 12 hours. MLR with cells was performed to confirm the behavior of siRNA in vivo.
  • the cell preparation method is as follows.
  • Spleen cells were collected from mice (stimulator: Balb / c (male 8 weeks old; 3 mice), responder: C57BL / 6 (male 8 weeks old; 3 mice)). Both Stimulator mice and Responder mice were administered intravenously with the siRNA / SPG complex 12 hours before harvesting the spleen cells. Hemolyzing agents (ammonium chloride, potassium) were added to lyse red blood cells (hemolytic agent 5 ml, RPMI 5 ml). 10% FBS (DS Pharma Biomedical), cells suspended in 5 ml of RPMI (4 ⁇ 10 5 / well), and stimulator-side spleen cells were treated with mitomycin C (MMC) (for the final 10 7 cells) 25 ⁇ g MMC added). Table 15 shows the MLR conditions.
  • MMC mitomycin C
  • FIG. 8 the value obtained by subtracting the value of the syngenic reaction from the value of the control allogenic response (splenocyte activity) (the value obtained by subtracting the number of cells of sample 6 from the number of cells of sample 6) is plotted as 100%. This shows how much the suppression of the lymphocyte proliferative reaction by the allogenic reaction can be suppressed by administration of the dA40 (s) -siCD40 (21nt) / SPG complex. This result also confirmed that the dA40 (s) -siCD40 (21nt) / SPG complex significantly suppresses the activation of lymphocytes when administered in vivo, similar to the result of (9-A) above. It was.
  • Example 12 Spleen cells were collected from Balb / c mice. Cells were seeded on a 24-well plate at 5 ⁇ 10 6 / well, and RPMI medium containing 10% by volume FBS was added to 1 ml / well. To the plate, add a control sample containing 300 ng / well of siRNA amount of dA40 (s) -siCD40 (21nt) / SPG complex using SPG modified with side chain of biotin, or PBS as siMock, CO 2 The cells were cultured overnight in an incubator (37 ° C).
  • Example 13 Using an ectopic heart transplantation model mouse, the effect of the dA40 (s) -siCD40 (21nt) / SPG complex in cardiac allograft was examined.
  • dA40 (s) -siCD40 (21nt) / SPG complex 2 ⁇ g / head was administered to Donor mice (C57 / BL10, male) and Recipient mice (CBA, male) from the tail vein.
  • the administration schedule is as follows. Donor mice were administered at a dose of 2 ⁇ g / head 3 days before (day (-3) and 1 day before (day -1), and Recipient mice were given 3 days (day -3) and 1 day before transplantation (day -3). On day IV-1), the same dose was administered at 2 mg / head. On day 0, the heart was removed from the Donor mouse and surgically transplanted to the Recipient mouse.
  • the recipient mice were further treated with dA40 (s) -siCD40 (21nt) at 1 day (day 1), 3 days (day 3), 5 days (day 5), and 7 days (day 7) after heart transplantation.
  • dA40 (s) -siCD40 (21nt) at 1 day (day 1), 3 days (day 3), 5 days (day 5), and 7 days (day 7) after heart transplantation.
  • dA40 (s) -siCD40 (21nt) at 1 day (day 1), 3 days (day 3), 5 days (day 5), and 7 days (day 7) after heart transplantation.
  • SPG complex was administered from the tail vein at a dose of 2 ⁇ g / head. After the administration, the pulsation of the transplanted heart of the Recipient mouse was observed over time.
  • dA40 (s) -siCD40 (21nt) / SPG complex dA40 (s) -siGAPDH (Glyceraldehyde-3-phosphate dehydrogenase) (21nt) / SPG complex was administered in the same amount, In the same manner as described above, the test was also performed in the case where the dA40 (s) -siCD40 (21nt) / SPG complex was not administered.
  • FIG. 9 The obtained results are shown in FIG. In FIG. 9, “siCD40 / SPG complex” indicates dA40 (s) -siCD40 (21nt) / SPG complex, and “siGAPDH / SPG complex” indicates dA40 (s) -siGAPDH (21nt) / SPG complex. Show. As is apparent from FIG. 9, when the dA40 (s) -siCD40 (21nt) / SPG complex was administered, the transplanted heart pulsated normally for a long time in all Recipient mice after transplantation. All Recipient mice survived after 90 days. On the other hand, when dA40 (s) -siGAPDH (21nt) / SPG complex was administered or nothing was administered, the survival rate of Recipient mice became 0% 10 days after transplantation.
  • dA40 (s) -siCD40 (21nt) / SPG complex 2 ⁇ g / head was administered only to donor mice (C57 / BL10, male) or only to Recipient mice (CBA, male), and the pulsation of the transplanted heart was observed.
  • CBA Recipient mice
  • dA40 (s) -siCD40 (21 nt) was effectively introduced into the antigen-presenting cells and suppressed the expression of CD40 and the activation of antigen-specific T cells.
  • Example 14 Using an ectopic heart transplantation model mouse, the immune tolerance effect of dA40 (s) -siCD40 (21nt) / SPG complex in adoptive transfer of adoptive immune cells was tested.
  • dA40 (s) -siCD40 (21nt) / SPG complex 2 ⁇ g / head was administered to the first Donor mouse (C57BL / 10, male) and the first Recipient mouse (CBA / N, male) from the tail vein.
  • the administration schedule is as follows.
  • the first Donor mice were administered at 2 ⁇ g / head 3 times before (day -3) and 1 day before (day -1), and the first recipient mice were given 3 days before (day -3) and 1 day before transplantation.
  • the dose was 2 mg / head once a day (day -1).
  • the heart was removed from the first Donor mouse and surgically transplanted to the first Recipient mouse.
  • dA40 (s) -siCD40 (day 1) day 1)
  • 3 days (day 3), 5 days (day 5), and 7 days (day 7) after the heart transplantation.
  • 21 nt) / SPG complex was administered at 2 ⁇ g / head at a time via the tail vein.
  • the pulsation of the transplanted heart of the first Recipient mouse was observed over time. Thereafter, when the number of pulsation days of the transplanted heart reached 30, the spleen cells were removed from the first recipient mouse, and 5 ⁇ 10 7 cells were administered to the new second recipient mouse (CBA / N, male) via the tail vein.
  • the heart was removed from a new second Donor mouse (C57BL / 10, male) and surgically transplanted to the second Recipient mouse (30 Day AT (B10 to CBA) group). . After the ectopic heart transplantation, the pulsation of the transplanted heart of the second Recipient mouse was observed over time.
  • Example 15 The immune tolerance effect of dA40 (s) -siCD40 (21nt) / SPG complex was tested by MLR. Specifically, MLR was performed by the method shown below.
  • Recipient Responder Cells Spleen cells were collected from mice (CBA, male), and T cells were collected using T fiber enrichment (nylon fiber) columns and prepared as Recipient cells.
  • BMDC bone marrow-derived dendritic cells
  • spleen cells were collected from mice (CBA, male), and then CD11c (+) dendritic cells were separated from the obtained spleen cells and prepared as Donor cells.
  • mice were removed from Donor mice and surgically transplanted to Recipient mice. After transplantation, the recipient mice were further treated with dA40 (s) -siCD40 (21nt) at 1 day (day 1), 3 days (day 3), 5 days (day 5), and 7 days (day 7) after heart transplantation.
  • dA40 (s) -siCD40 (21nt) at 1 day (day 1), 3 days (day 3), 5 days (day 5), and 7 days (day 7) after heart transplantation.
  • / SPG complex was administered at 2 ⁇ g / head at a time via the tail vein. After the administration, the pulsation of the transplanted heart of the Recipient mouse was observed over time. Thereafter, when the number of pulsation days of the transplanted heart reached 30, spleen cells were collected from the Recipient mouse.
  • CD4 (+) CD25 (-) T cells, CD11c (-) T cells (macrophages), CD4 (+) CD25 (+) T cells (Treg, Regulatory T cells) and CD11C (+) dendritic cells were collected and used as regulator cells.
  • spleen cells were collected from a mouse (CBA, male) not administered with dA40 (s) -siCD40 (21 nt) / SPG complex and ectopic heart transplantation.
  • CD11c (+) dendritic cells derived from Naive CBA were separated from the obtained spleen cells and prepared as stimulator cells.
  • Donor cells, Regulator cells, and Recipient cells were mixed in wells containing 10% FBS / RPMI under MLR conditions and cultured in a 7 ° C., 5% CO 2 environment. After culture, the proliferation of recipient cells was measured by an assay using chemiluminescence by BrdU incorporation (Cell Proliferation ELISA, BrdU) (Roche Applied Science).
  • the MLR conditions are shown in Table 16 below.
  • nucleotide sequences of siLuc and siCD40 used in Examples 1 to 15 are as shown in Table 17 below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'objectif de la présente invention est de fournir un agent médicinal et un procédé, chacun desquels pouvant induire efficacement une tolérance immunitaire spécifique d'un donneur dans un receveur dans une thérapie par transplantation. L'invention concerne un complexe d'ARNsi pour un facteur de costimulation et le schizophyllane pouvant être administré à une cellule exprimant la Dectine-1, qui est une cellule apte à reconnaître le schizophyllane spécifiquement, pour réguler la fonction de la cellule exprimant la Dectine-1 et, par conséquent, pouvant induire efficacement un effet immunosuppresseur ainsi qu'une tolérance immunitaire.
PCT/JP2012/067950 2010-08-10 2012-07-13 Inducteur de tolérance immunitaire WO2013021784A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP12822876.4A EP2742944B1 (fr) 2011-08-10 2012-07-13 Inducteur de tolérance immunitaire
ES12822876.4T ES2684969T3 (es) 2010-08-10 2012-07-13 Inductor de tolerancia inmune
US14/237,763 US9801929B2 (en) 2011-02-28 2012-07-13 Immune tolerance inducer
JP2013527942A JP6210879B2 (ja) 2011-08-10 2012-07-13 免疫寛容誘導剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JPPCT/JP2011/068265 2011-08-10
PCT/JP2011/068265 WO2012020795A1 (fr) 2010-08-10 2011-08-10 Complexe acide nucléique/polysaccharide
JPPCT/JP2012/053583 2012-02-15
PCT/JP2012/053583 WO2012117855A1 (fr) 2011-02-28 2012-02-15 Complexe (acide nucléique)-polysaccharide

Publications (1)

Publication Number Publication Date
WO2013021784A1 true WO2013021784A1 (fr) 2013-02-14

Family

ID=47669272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/067950 WO2013021784A1 (fr) 2010-08-10 2012-07-13 Inducteur de tolérance immunitaire

Country Status (3)

Country Link
EP (1) EP2742944B1 (fr)
JP (1) JP6210879B2 (fr)
WO (1) WO2013021784A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018097296A1 (fr) * 2016-11-28 2018-05-31 ナパジェン ファーマ，インコーポレテッド Arnsi chimiquement modifié
WO2019230898A1 (fr) * 2018-05-30 2019-12-05 ナパジェン ファーマ，インコーポレテッド Composition pharmaceutique contenant un complexe d'arnsi chimiquement modifié et de schizophyllane

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2653639T3 (es) * 2011-02-28 2018-02-08 Napajen Pharma, Inc. Complejo ácido nucleico-polisacárido
US20200085758A1 (en) * 2016-12-16 2020-03-19 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501607A (ja) * 1996-09-18 2001-02-06 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 免疫調節のためのｃｄ４５ｒ白血球抗原に対する抗体の利用
WO2009078470A1 (fr) 2007-12-18 2009-06-25 National Institute Of Advanced Industrial Science And Technology Complexe de polysaccharide et d'arn double brin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1807050A1 (fr) * 2004-11-05 2007-07-18 Novosom AG Ameliorations apportees a des compositions pharmaceutiques comprenant un oligonucleotide comme agent actif
WO2007058323A1 (fr) * 2005-11-17 2007-05-24 Napa Jenomics Co., Ltd. Procédé pour la production d'un médicament de type acide nucléique fonctionnel lié à un homopolymère d'un acide nucléique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501607A (ja) * 1996-09-18 2001-02-06 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 免疫調節のためのｃｄ４５ｒ白血球抗原に対する抗体の利用
WO2009078470A1 (fr) 2007-12-18 2009-06-25 National Institute Of Advanced Industrial Science And Technology Complexe de polysaccharide et d'arn double brin

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
A.C.S., vol. 38, no. 1, 1997, pages 253
BULL. CHEM. SOC. JPN., vol. 77, 2004, pages 1101 - 1110
CARBOHYDRATE RESEARCH, vol. 89, 1981, pages 121 - 135
EXP NEUROL., vol. 186, no. 1, March 2004 (2004-03-01), pages 59 - 69
HUANG,L. ET AL.: "Effect of silencing CD86 expression on antigen presenting cells by siRNA on activation of T lymphocytes", ZHONGGUO MIANYIXUE ZAZHI, vol. 27, no. 8, August 2011 (2011-08-01), pages 681 - 685, 695, XP008170354 *
KARIMI,M.H. ET AL.: "Comparison of three techniques for generation of tolerogenic dendritic cells: siRNA, oligonucleotide antisense, and antibody blocking", HYBRIDOMA, vol. 29, no. 6, 2010, pages 473 - 480, XP055120698 *
MIZU,M. ET AL.: "Enhancement of the antisense effect of polysaccharide-polynucleotide complexes by preventing the antisense oligonucleotide from binding to proteins in the culture medium", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 77, no. 6, 2004, pages 1101 - 1110, XP008168537 *
See also references of EP2742944A4 *
TRANSPLANTATION, vol. 75, no. 5, 2003, pages 637 - 643

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018097296A1 (fr) * 2016-11-28 2018-05-31 ナパジェン ファーマ，インコーポレテッド Arnsi chimiquement modifié
JPWO2018097296A1 (ja) * 2016-11-28 2018-11-29 ナパジェン ファーマ, インコーポレテッドNapaJen Pharma, Inc. 化学修飾ｓｉＲＮＡ
US11203755B2 (en) 2016-11-28 2021-12-21 Napajen Pharma, Inc. Chemically-modified siRNA
WO2019230898A1 (fr) * 2018-05-30 2019-12-05 ナパジェン ファーマ，インコーポレテッド Composition pharmaceutique contenant un complexe d'arnsi chimiquement modifié et de schizophyllane

Also Published As

Publication number Publication date
EP2742944A1 (fr) 2014-06-18
EP2742944A4 (fr) 2015-01-21
EP2742944B1 (fr) 2018-06-27
JPWO2013021784A1 (ja) 2015-03-05
JP6210879B2 (ja) 2017-10-11

Similar Documents

Publication Publication Date Title
US11850284B2 (en) Compositions and methods for delivery of nucleic acids to cells
JP2021503286A (ja) Ｍｓｃ由来エキソソームの製造方法
WO2012014945A1 (fr) Nouvel acide nucléique ayant une activité d'adjuvant et son utilisation
US10519441B2 (en) Use of miRNA-214 inhibitor in inhibiting regulatory cells
JP6210879B2 (ja) 免疫寛容誘導剤
US20230265214A1 (en) Compositions and methods for delivery of nucleic acids to cells
JP6124785B2 (ja) 核酸多糖複合体
WO2012020795A1 (fr) Complexe acide nucléique/polysaccharide
US20240182543A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
KR20140139512A (ko) 페리오스틴 유전자의 발현 억제 핵산 분자, 페리오스틴 유전자의 발현 억제 방법 및 그 용도
CA3044789A1 (fr) Arnsi chimiquement modifie
US20210154309A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING COMPLEX OF CHEMICALLY-MODIFIED siRNA AND SCHIZOPHYLLAN
WO2024081736A2 (fr) Compositions et procédés d'utilisation d'anticorps de pénétration cellulaire
JP2023522985A (ja) Ｈｌａクラスｉ ｍｈｃの細胞切除

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12822876

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013527942

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14237763

Country of ref document: US